Welcome to our dedicated page for TenX Keane Acquisition SEC filings (Ticker: TENKU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings associated with TENKU trace the evolution from TenX Keane Acquisition, a Nasdaq-listed special purpose acquisition company, to the oncology-focused public company Citius Oncology, Inc. After TenX shareholders approved the merger with Citius Pharmaceuticals, Inc.’s oncology subsidiary, subsequent registration statements and current reports are filed under the Citius Oncology, Inc. name and a different ticker symbol.
These filings include registration statements on Form S-1 and S-1/A that describe Citius Oncology’s capital-raising plans, the structure of offerings involving common stock, pre-funded warrants, and common warrants, and the role of the placement agent. The documents outline how Citius Oncology’s common stock trades on Nasdaq under the symbol CTOR and explain the terms under which additional securities may be issued.
Current reports on Form 8-K detail material events for Citius Oncology, Inc., such as placement agency agreements, securities purchase agreements, registered direct offerings, private placements of warrants, and amendments to promissory notes between Citius Oncology and Citius Pharmaceuticals, Inc. These reports also reference press releases announcing the pricing and closing of offerings and describe restrictions on additional issuances for specified periods.
On this page, users can review the historical SPAC-related disclosures tied to TenX Keane Acquisition as well as the later filings of Citius Oncology, Inc. that are linked to the TENKU symbol’s corporate successor. Stock Titan’s tools can help readers navigate registration statements, 8-Ks, and other documents, and understand how the original SPAC structure transitioned into an operating oncology company through the completed business combination.
Citius Oncology, Inc. entered into a placement agency and securities purchase agreement for a “best-efforts” registered direct offering of 5,142,858 shares of common stock, paired with private Warrants to purchase up to 5,142,858 additional shares. The Shares and Warrants were sold together at a combined price of $1.75 per unit, generating estimated net proceeds of about $7.48 million after fees and expenses, with the Offering closing on September 10, 2025.
The Warrants have an exercise price of $1.84 per share, become exercisable six months after issuance, and expire five and a half years after issuance. Citius paid Maxim Group LLC a 7.0% cash fee on aggregate gross proceeds and up to $100,000 of expenses, and issued Placement Agent Warrants for 205,714 shares at a $1.92 exercise price on similar timing. The company also amended an existing promissory note to make its maturity the date on which Citius completes capital raises totaling at least $30 million through specified financing or royalty monetization transactions.
TenX Keane Acquisition Unit Prospectus Supplement describes a securities offering for TenX Keane Acquisition ("TENKU") that includes common shares and warrants and outlines underwriting terms, dilution and material risks. The placement agent fee is described as a cash fee equal to 7.0% of the aggregate purchase price and the underwriter will receive warrants equal to 4.0% of the shares sold. The offering contemplates selling 5,142,858 shares on a best-efforts basis and a concurrent private placement of unregistered warrants for 5,142,858 shares at an exercise price of $1.84 per share exercisable six months after issuance and expiring after five and one-half years. The document discloses substantial doubt about the company’s ability to continue as a going concern and states the company will need substantial additional funds even after this offering. It lists key risks including commercialization and supply of LYMPHIR, dependence on third parties, Nasdaq listing compliance, potential litigation related to the Merger, and material dilution from outstanding warrants, placement agent warrants, options and shares reserved under equity plans.
Citius Oncology, Inc. filed an S-3 shelf registering up to $200,000,000 of securities and a resale prospectus for up to 7,090,909 shares issuable upon warrant exercise. The company discloses its independent auditor included an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern and states it will need substantial additional funds even after this offering. The filing highlights material risks tied to commercializing LYMPHIR, procuring cGMP commercial-scale supply, dependence on third parties, uncertainties in preclinical and clinical development, potential inability to realize benefits of a prior merger, ongoing evaluations of strategic alternatives, compliance with Nasdaq listing standards, and possible litigation related to the merger. It states 78,370,584 shares were outstanding as of August 31, 2025, and estimates 85,461,493 shares outstanding after the offering (assuming full registration outcomes).
Citius Oncology, Inc. filed a prospectus supplement to its Form S-1 registration statement that had been declared effective on July 15, 2025. The supplement relates to common stock and warrants Citius Oncology sold in a public offering on July 17, 2025. The company explains that this supplement is needed to keep the S-1 registration statement current with its recently filed Quarterly Report on Form 10-Q because it is not yet eligible to incorporate that report by reference into the S-1.
Citius Oncology, Inc. filed a Form 8-K dated August 12, 2025, reporting that it issued a press release announcing its results of operations for the third quarter of fiscal 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference into the report.
The company clarifies that the Item 2.02 disclosure (including Exhibit 99.1) is furnished and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act. Item 9.01 lists Exhibits 99.1 and 104 (cover page interactive data), and the filing is signed by Leonard Mazur, Chairman and Chief Executive Officer.
Citius Oncology, Inc. is commercializing LYMPHIR (denileukin diftitox), an FDA-approved immunotherapy for cutaneous T-cell lymphoma, and is preparing for a U.S. commercial launch in the second half of 2025 with distribution agreements in place with Cardinal Health and Cencora. The company has built inventory of $17.2 million and reports operational readiness to transition from development to commercial operations.
Financially, the company reported a $19.76 million net loss for the nine months ended June 30, 2025, an accumulated deficit of $59.04 million, only $112 in cash and negative working capital of approximately $34.7 million at June 30, 2025. Material near-term obligations include a remaining $22.5 million milestone to Dr. Reddy's, a $5.9 million Eisai milestone included in license payable, and minimum supply commitments of approximately $18.3 million (manufacturing) plus $4.5 million (packaging). The company completed a public offering on July 17, 2025 raising gross proceeds of $9.0 million (net approx. $7.44 million), which the company states extends runway through September 2025 but additional financing will be required thereafter.